Toronto Dominion Bank grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 4.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 41,066 shares of the biotechnology company’s stock after acquiring an additional 1,749 shares during the quarter. Toronto Dominion Bank’s holdings in BioMarin Pharmaceutical were worth $3,403,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Steward Partners Investment Advisory LLC raised its holdings in BioMarin Pharmaceutical by 325.5% during the first quarter. Steward Partners Investment Advisory LLC now owns 2,451 shares of the biotechnology company’s stock worth $189,000 after purchasing an additional 1,875 shares in the last quarter. Arizona State Retirement System raised its stake in BioMarin Pharmaceutical by 2.4% during the 1st quarter. Arizona State Retirement System now owns 51,105 shares of the biotechnology company’s stock worth $3,940,000 after acquiring an additional 1,184 shares in the last quarter. abrdn plc lifted its position in BioMarin Pharmaceutical by 14.1% in the first quarter. abrdn plc now owns 23,058 shares of the biotechnology company’s stock valued at $1,790,000 after acquiring an additional 2,849 shares during the last quarter. Banque Pictet & Cie SA acquired a new position in BioMarin Pharmaceutical in the first quarter valued at $2,230,000. Finally, Clearstead Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 10,036.1% during the first quarter. Clearstead Advisors LLC now owns 3,649 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 3,613 shares during the last quarter. Institutional investors and hedge funds own 94.84% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on BMRN. StockNews.com started coverage on BioMarin Pharmaceutical in a report on Wednesday, October 12th. They issued a “buy” rating for the company. Wedbush reissued a “neutral” rating and issued a $74.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, September 13th. SVB Leerink lifted their target price on shares of BioMarin Pharmaceutical from $115.00 to $122.00 and gave the company an “outperform” rating in a report on Thursday, August 4th. Piper Sandler increased their price target on shares of BioMarin Pharmaceutical from $125.00 to $128.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 9th. Finally, Stifel Nicolaus lifted their price objective on shares of BioMarin Pharmaceutical to $104.00 in a research note on Wednesday, September 28th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $111.07.
Insider Transactions at BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Performance
NASDAQ BMRN opened at $97.79 on Friday. The stock has a market capitalization of $18.14 billion, a price-to-earnings ratio of 232.83, a PEG ratio of 2.06 and a beta of 0.34. The business’s 50 day moving average is $86.93 and its two-hundred day moving average is $85.62. BioMarin Pharmaceutical Inc. has a 12-month low of $70.73 and a 12-month high of $99.74. The company has a current ratio of 5.15, a quick ratio of 3.54 and a debt-to-equity ratio of 0.24.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last announced its quarterly earnings data on Wednesday, October 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). BioMarin Pharmaceutical had a return on equity of 2.50% and a net margin of 4.18%. The business had revenue of $505.30 million for the quarter, compared to analyst estimates of $516.03 million. During the same period in the prior year, the company earned ($0.03) EPS. The company’s revenue was up 23.6% on a year-over-year basis. Research analysts expect that BioMarin Pharmaceutical Inc. will post 0.88 EPS for the current year.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
- Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.